Table 1

Clinical characteristics at baseline of the cohort and comparison according to the cell lineage

VariableWhole cohort (n = 170)T-LGL (n = 120)CLPD-NKs (n = 50)P
Age    .74 
    Median, y 64 65 61  
    Range, y 20-90 20-87 27-90  
Sex, no. (%)    .9 
    Male 55 (94) 55 (66) 56 (28)  
    Female 45 (86) 45 (54) 44 (22)  
Symptoms at diagnosis, no. (%) 53 (90) 53 (63) 54 (27) .8 
Neutropenia, no. (%)* 62 (105) 64 (75) 60 (30) .7 
Lymphocytosis, no. (%) 54 (92) 50 (60) 64 (32) .07 
Anemia, no. (%) 30 (52) 31 (37) 30 (15) .9 
Thrombocytopenia, no. (%)§ 14 (24) 13 (16) 16 (8) .7 
LGL count in PB, × 109/L    .5 
    Median 3.4 3.1 3.7  
    Range 0.2-22 0.3-22 0.9-13  
Splenomegaly, no. (%) 21 (37) 25 (31) 21 (6) .4 
Presence of MGUS, no. (%) 21 (36) 22 (26) 20 (10) .9 
Associated autoimmune disease     
    RA, no. (%) 10 (17) 11 (14) 6 (3) .10 
    AIHA, no. (%) 7 (12) 5 (6) 12 (6) .15 
Associated BM disorder     
    MDS, no. (%) 5 (9) 6 (7) 4 (2) .25 
    PRCA, no. (%) 5 (8) 6 (7) 2 (1) .15 
Presence of B-cell malignancy, no. (%) 9 (15) 10 (12) 6 (3) .3 
Treatment lines    .3 
    Median 1.5 1.7 1.2  
Patients with somatic mutation in STAT3-SH2 domain, no. (%) 28 (48) 27 (33) 30 (15) .6 
VariableWhole cohort (n = 170)T-LGL (n = 120)CLPD-NKs (n = 50)P
Age    .74 
    Median, y 64 65 61  
    Range, y 20-90 20-87 27-90  
Sex, no. (%)    .9 
    Male 55 (94) 55 (66) 56 (28)  
    Female 45 (86) 45 (54) 44 (22)  
Symptoms at diagnosis, no. (%) 53 (90) 53 (63) 54 (27) .8 
Neutropenia, no. (%)* 62 (105) 64 (75) 60 (30) .7 
Lymphocytosis, no. (%) 54 (92) 50 (60) 64 (32) .07 
Anemia, no. (%) 30 (52) 31 (37) 30 (15) .9 
Thrombocytopenia, no. (%)§ 14 (24) 13 (16) 16 (8) .7 
LGL count in PB, × 109/L    .5 
    Median 3.4 3.1 3.7  
    Range 0.2-22 0.3-22 0.9-13  
Splenomegaly, no. (%) 21 (37) 25 (31) 21 (6) .4 
Presence of MGUS, no. (%) 21 (36) 22 (26) 20 (10) .9 
Associated autoimmune disease     
    RA, no. (%) 10 (17) 11 (14) 6 (3) .10 
    AIHA, no. (%) 7 (12) 5 (6) 12 (6) .15 
Associated BM disorder     
    MDS, no. (%) 5 (9) 6 (7) 4 (2) .25 
    PRCA, no. (%) 5 (8) 6 (7) 2 (1) .15 
Presence of B-cell malignancy, no. (%) 9 (15) 10 (12) 6 (3) .3 
Treatment lines    .3 
    Median 1.5 1.7 1.2  
Patients with somatic mutation in STAT3-SH2 domain, no. (%) 28 (48) 27 (33) 30 (15) .6 

PB indicates peripheral blood; MGUS, monoclonal gammopathy of undetermined significance; MDS, myelodysplastic syndrome; STAT3, signal transducer and activator of transcription 3; and SH2, Src homology 2 domain.

*

Absolute neutrophil count ≤ 1.5 × 109/L.

Absolute lymphocyte count ≥ 4 × 109/L.

Hemoglobin ≤ 10 g/dL.

§

Platelet count ≤ 100 × 109/L.

Close Modal

or Create an Account

Close Modal
Close Modal